![]() ![]() 3-dose primary series of Pfizer-BioNTech COVID-19 Vaccine (vials with maroon caps and labels with maroon borders) for Doses 1 and 2 and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (vials with maroon caps and labels with maroon borders) for Dose 3, OR.Individuals 4-5 years of age may receive either.Individual who already completed 3-dose primary series with original (monovalent) Pfizer-BioNTech COVID-19 vaccine will not be eligible for a booster dose of an updated bivalent vaccine at this time.Individuals who have not yet received 3-dose primary series of the Pfizer-BioNTech COVID-19 Vaccine or have not yet received 3rd dose of their primary series may receive (bivalent) Pfizer-BioNTech COVID-19 vaccine as 3rd dose in their primary series following 2 doses of monovalent Pfizer-BioNTech COVID-19 vaccine.Initial 2 doses are administered 3 weeks apart, followed by third dose administered at least 8 weeks after second dose.3-dose primary series: 0.2 mL (3 mcg maroon cap and label border vial) IM. ![]() Moderately or severely immunocompromised patients: Administer a third primary dose at least 4 weeks following the second dose.2-dose primary series: 0.2 mL (10 mcg orange cap and label border vial) IM x2 doses administered 3 weeks apart.Administer Moderna or Pfizer omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster at least 2 months after completion of primary vaccination or most recent booster dose with any authorized/approved monovalent COVID-19 vaccine.3-8 week interval between primary doses.Moderately or severely immunosuppressed: Administer a third primary dose at least 4 weeks after second dose.2-dose primary series: 0.3 mL (30 mcg) IM x2 doses administered 3 weeks apart.<6 months: Safety and efficacy not established 12-17 years (full FDA approval) Indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals aged ≥6 months Aged 6 months to Aged 5-11 years: Orange cap and label border multiple-dose vial (after dilution yields ten doses/vial).Aged ≥12 years: Purple cap and label border multiple-dose vial (after dilution yields six doses/vial).Limitations of effectiveness: May not protect all vaccine recipients Administer either Pfizer or Moderna omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster at least 2 months after completion of primary vaccination or most recent booster dose with any authorized/approved monovalent COVID-19 vaccine. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |